Important note before you read further: I do not supply, source, or facilitate access to controlled substances or plant medicines of any kind. This post is an educational overview of published scientific literature. Nothing here constitutes medical advice, and nothing here should be interpreted as encouragement to use any illegal substance. What I offer as a physician is what I describe at the end of this piece: risk stratification, harm reduction, preparation, and integration support for patients who are making their own informed decisions about their own health.

‍

I want to start by being honest about something. When I was training in emergency medicine, psychedelics were not a clinical topic. They were something people occasionally arrived in the emergency department having taken too much of. We managed the acute presentation and moved on. Nobody talked about the therapeutic potential. Nobody talked about the neuroscience. The assumption, shared by most of medicine, was that these substances were drugs of abuse with no legitimate medical application and nothing to teach us.

‍

That assumption is no longer scientifically defensible. Over the last 15 years, some of the world's most rigorous research institutions, including Johns Hopkins, NYU, Imperial College London, and UCSF, have produced a body of clinical evidence on psychedelic compounds that has forced the medical establishment to pay attention. The FDA has granted breakthrough therapy designation to psilocybin for treatment-resistant depression and to MDMA for post-traumatic stress disorder. These are not small designations. They represent the FDA's acknowledgment that the existing evidence is sufficiently promising to warrant expedited development.

‍

I believe this is one of the most important developments in neuropsychiatry in decades. And for a longevity practice focused on brain health, cognitive performance, and the upstream drivers of neurodegeneration, ignoring it would be a clinical mistake.

‍

"We have spent 50 years classifying these compounds based on their potential for misuse. The next 50 years will be spent understanding their potential for healing."

‍

What plant medicines actually do in the brain

‍

The nootropic and therapeutic effects of classical psychedelics, primarily psilocybin, LSD, DMT, and mescaline, are mediated primarily through agonism at the 5-HT2A serotonin receptor, which is densely expressed in the prefrontal cortex. But the downstream effects go considerably beyond serotonin signaling, and they are the reason these compounds have attracted serious neuroscience attention.

‍

BDNF upregulation

Psilocybin and LSD significantly increase brain-derived neurotrophic factor, the primary growth hormone of the brain. BDNF promotes neurogenesis, synaptic plasticity, and the survival of existing neurons. It is the molecular substrate of learning itself.

Default mode network disruption

Classical psychedelics dramatically reduce activity in the default mode network, the self-referential rumination network overactive in depression, anxiety, and addiction. This disruption is associated with the dissolution of rigid, self-limiting thought patterns that characterize many psychiatric conditions.

‍

Neuroplasticity window

Psychedelic experiences open a heightened period of neuroplasticity lasting 24 to 72 hours post-experience, during which the brain is unusually receptive to new patterns, perspectives, and behavioral change. This is the biological basis of the integration process.

‍

Entropy and cognitive flexibility

Psychedelics increase brain entropy, meaning they temporarily allow more diverse, less constrained neural communication patterns. This appears to underlie the characteristic expansion of perspective and the loosening of entrenched cognitive habits that users describe.

‍

Anti-inflammatory signaling

Emerging research suggests that 5-HT2A agonism has anti-inflammatory effects at the cellular level, with some compounds showing direct inhibition of inflammatory cytokine production. Given that neuroinflammation is a primary driver of both depression and neurodegeneration, this pathway is attracting significant research interest.

‍

Synaptogenesis

Recent studies, including work from David Olson's lab at UC Davis, have shown that even sub-perceptual doses of certain psychedelics promote the growth of new dendritic spines and synaptic connections, independent of the subjective experience. This is perhaps the most significant nootropic finding in the field.

‍

The clinical evidence: what the trials actually show

‍

This is not anecdote. The clinical research on psychedelics is now extensive enough to draw meaningful conclusions, and the results across multiple conditions are consistently striking.

‍

DEPRESSION

Treatment-resistant depression

A 2021 randomized controlled trial at Johns Hopkins found that two doses of psilocybin produced rapid, sustained reductions in depression severity in treatment-resistant patients, with 71% showing significant response and 54% in remission at four weeks. Effects were maintained at 12-month follow-up in a substantial proportion of participants.

Davis et al., JAMA Psychiatry, 2021

‍

PTSD

MDMA-assisted therapy

Phase 3 trials of MDMA-assisted therapy for PTSD showed that 67% of participants no longer met diagnostic criteria for PTSD after treatment, compared to 32% in the placebo group. This is a therapeutic response rate that no existing PTSD pharmacotherapy comes close to matching.

Mitchell et al., Nature Medicine, 2021

‍

ADDICTION

Alcohol and tobacco cessation

A Johns Hopkins pilot study found that 80% of participants who received psilocybin-assisted therapy for tobacco addiction were abstinent at six months, compared to roughly 35% for the most effective existing pharmacotherapies. Similar results have been found for alcohol use disorder across multiple trials.

Johnson et al., Journal of Psychopharmacology, 2014

‍

OCD

Obsessive-compulsive disorder

A small but carefully conducted Yale study found that all nine OCD patients showed marked decreases in symptom severity following psilocybin administration, with effects independent of the intensity of the acute experience. OCD is one of the most refractory psychiatric conditions and remains poorly served by existing pharmacotherapy.

Moreno et al., Journal of Clinical Psychiatry, 2006

‍

END-OF-LIFE

Existential anxiety and palliative care

Multiple studies at Johns Hopkins and NYU have shown that a single psilocybin session produces sustained reductions in death anxiety, depression, and existential distress in patients with life-threatening diagnoses, with effects lasting six months or longer in the majority of participants.

Ross et al., Journal of Psychopharmacology, 2016

‍

NOOTROPIC USE

Cognitive flexibility and creativity

Controlled studies examining sub-threshold doses have found improvements in convergent and divergent thinking, cognitive flexibility, and measures of open-mindedness. These effects appear to be related to the transient increase in neural entropy and the loosening of habitual cognitive patterns that psychedelics produce even at doses below the threshold of perceptual effects.

Prochazkova et al., Psychopharmacology, 2018

Microdosing versus macrodosing: two different tools

‍

One of the most important distinctions in this space, and one that is often lost in both the enthusiast literature and the mainstream media coverage, is that microdosing and macrodosing are not the same intervention and do not work through the same mechanisms.

‍

Microdosing has attracted enormous popular attention, but it is worth noting that the clinical trial evidence predominantly supports macrodosing protocols. The most rigorous microdosing research, including Imperial College London's controlled microdosing study, found that many reported benefits of microdosing may be partially attributable to expectancy effects when controlling carefully for placebo. This does not mean microdosing does not work. It means the evidence base is less mature and the mechanisms are less well characterized than for full-dose experiences. Both deserve continued serious investigation.

‍

Set and setting: why this is not optional

‍

The most important concept in the entire psychedelic medicine literature is set and setting, a framework developed by Timothy Leary and refined by modern clinical researchers into something considerably more rigorous than its origins might suggest. Set refers to the mindset, intentions, expectations, psychological history, and emotional state the person brings into the experience. Setting refers to the physical environment, the level of safety and trust, the presence or absence of a guide, and the quality of the support structure around the experience.

‍

This is not a soft consideration. The clinical trial data makes clear that the therapeutic outcomes of psychedelic experiences are profoundly shaped by set and setting. The same compound, at the same dose, in the same person, can produce a deeply healing experience in one context and a genuinely destabilizing one in another. This is one of the core reasons that the recreational and the therapeutic use of these substances produce such different outcomes in the population data, and it is one of the reasons that physician involvement in the preparation process has genuine clinical value.

‍

A legitimate guide, meaning someone with formal training in psychedelic facilitation from an established program and not simply someone with personal experience, is not a luxury for a macrodose experience. It is a clinical necessity. The guide's role is not to manage the experience itself, which largely unfolds on its own, but to create the conditions of safety and trust that allow the experience to be therapeutically productive rather than overwhelming. The integration work that happens in the days and weeks following the experience is, in many ways, where the actual therapeutic benefit is consolidated, and a skilled guide is essential for that process as well.

‍

What I can offer as a physician

‍

I want to be clear again about what I do not do. I do not source, supply, or prescribe controlled substances outside of legal frameworks. I do not run psychedelic sessions. I am not a guide, and I do not function as one.

‍

What I do offer is something that most people approaching plant medicine in Las Vegas cannot currently access: a physician who is knowledgeable, non-judgmental, and clinically equipped to support them before, during the preparation phase, and after their experience.

‍

What physician support actually looks like in this space

Risk stratification: Not everyone is a good candidate for psychedelic experiences, and some people have contraindications that are genuinely important. Personal or family history of psychosis or schizophrenia spectrum disorders significantly elevates risk. Certain cardiac conditions matter with MDMA. Current medications, particularly SSRIs and lithium, interact in ways that range from blunting the experience to creating dangerous physiological effects. I can review your medical history, your medications, and your psychiatric background and give you an honest assessment of your risk profile before you make a decision.

‍

Medication review and washout guidance: SSRIs, SNRIs, MAOIs, tricyclics, lithium, and several other common medications have meaningful interactions with psychedelic compounds. The clinical guidance on washout periods, timing, and alternatives is nuanced and not something to navigate from a Reddit thread. I can review your current regimen and discuss what a medically sound approach looks like.

‍

Substance testing guidance: One of the most underappreciated risks in this space is not the compound itself but what it is adulterated with. Fentanyl contamination of the drug supply has reached psychedelic compounds in some markets. I can discuss reagent testing, lab testing services, and harm reduction strategies that meaningfully reduce the risk of unknowing exposure to dangerous adulterants.

‍

Expectation setting and preparation: Clinical trials invest significant time in preparation sessions before any participant receives a psychedelic compound, and this investment predicts therapeutic outcome. I can discuss what the research shows about how to approach an experience intentionally, what the likely phenomenology includes, how to work with difficult material rather than against it, and how to set meaningful intentions that support integration afterward.

‍

Guide referral: I maintain awareness of the trained facilitation community in Las Vegas and more broadly, and I can connect patients with guides who have legitimate training backgrounds and whose approach aligns with the clinical literature. This is not a formal referral in the medical-legal sense. It is the kind of informed guidance that comes from being embedded in this space professionally.

‍

Integration support: The neuroplasticity window following a macrodose experience is one of the most important and most underutilized aspects of this work. I can provide medical context for what is happening neurobiologically in the days following an experience, support the behavioral and lifestyle changes that consolidate therapeutic gains, and help patients make sense of difficult material that may have surfaced. This is where the long-term benefit is built.

‍

NAD+ and nutritional recovery support: As I have written about separately, the Festival Body Protocol at OCM addresses the physiological recovery needs following experiences that involve MDMA or other compounds with NAD+ depleting effects. Methyl donors, magnesium, NAC, and structured NAD+ restoration are evidence-informed strategies for supporting neurological recovery that I can discuss and prescribe as appropriate.

‍

The honest risk picture

‍

I would not be writing this as a physician if I were not willing to be honest about the risks alongside the benefits. Classical psychedelics like psilocybin have a remarkably favorable physiological safety profile. They are non-addictive, they are not neurotoxic at standard doses, and there are no recorded deaths from psilocybin alone in the clinical or epidemiological literature. The primary risks are psychological rather than physiological: acute anxiety, panic, and disorientation during the experience, and in a small number of cases, prolonged psychological difficulty in people with predisposing vulnerabilities.

‍

MDMA carries a different and more substantial physiological risk profile, particularly with repeated use, hyperthermia, hyponatremia in the context of overhydration, and serotonin syndrome if combined with serotonergic medications. These are real risks that require real harm reduction knowledge to navigate.

‍

Ayahuasca and other DMT-containing plant medicines involve potent MAOI activity that creates significant drug interaction risks and contraindications. The ceremonial context in which they are traditionally used provides a degree of structure and oversight that matters clinically.

‍

The common thread across all of these is that risk is not fixed. It is a function of the person, their history, their medications, the substance and its purity, the dose, the setting, and the quality of support around them. Physician involvement does not eliminate risk. But it meaningfully reduces the avoidable portion of it.

‍

A word on the ancient lineage

‍

The compounds we are now studying in clinical trials at Johns Hopkins and Imperial College London were not discovered by pharmaceutical companies. They have been used in structured, intentional, ceremonially held contexts by indigenous cultures across Mesoamerica, the Amazon basin, and elsewhere for thousands of years. Peyote ceremonies in the Native American Church, ayahuasca work in Shipibo and other Amazonian traditions, psilocybin mushroom use in Mazatec healing ceremonies, these are not primitive fumbling toward pharmacological truth. They are sophisticated, culturally embedded technologies for healing and transformation that developed over centuries of careful human observation.

‍

Modern psychedelic science is, in many respects, catching up to what these traditions already knew: that these experiences, held with intention, reverence, and skilled support, can produce genuine and lasting healing. The language we use is different. The setting is different. But the underlying respect for the power of these medicines, and the insistence that they require proper preparation and guidance, is the same.

‍

I find that perspective important to hold alongside the clinical trial data. These are not just molecules. They are part of a long human story about healing, consciousness, and what it means to take the inner life seriously.

‍

If you are considering plant medicine as part of your health and healing journey and want to approach it with medical oversight, proper risk assessment, and physician-guided preparation, I am one of the very few physicians in Las Vegas willing to have this conversation seriously and without judgment.

‍

Book a consultation with Outlive Concierge Medicine and let's talk about what a responsible, informed approach looks like for you specifically.

‍